Business Context and Reporting Period
This Form 8-K was filed by vTv Therapeutics Inc. on September 6, 2018, reporting an event that occurred on the same date. The company is incorporated in Delaware and identifies as an emerging growth company.
Key Financial Metrics
The filing details a specific capital raise event rather than periodic financial performance metrics such as revenue or operating margins.
- Capital Raised: $2.5 million
- Shares Issued: 1,879,699 shares of Class A common stock
- Price Per Share: $1.33
- Investor: MacAndrews & Forbes Group LLC
The filing text does not provide clear values for revenue, profit, cash flow, debt, or liquidity positions outside of this transaction.
Material Changes
The material change reported is the unregistered sale of equity securities. The Company exercised its right under a letter agreement dated July 30, 2018, to require the Investor to purchase the shares. This transaction increased the Company's cash position by $2.5 million and diluted existing shareholders through the issuance of new Class A common stock.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the transaction details are qualified by reference to the 2018 Letter Agreement. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the terms of the July 30, 2018 Letter Agreement filed as an exhibit to the subsequent Form 10-Q.
- Confirm the total number of outstanding shares post-transaction to assess dilution impact.
- Review the Company's cash burn rate to determine the runway provided by the $2.5 million infusion.
- Check for any subsequent filings regarding the use of proceeds from this capital raise.